FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy

In briefing documents published Monday ahead of an advisory committee meeting for deramiocel, the FDA disagreed with Capricor’s assertion that a Phase 3 trial met its primary outcome measures.